Ignite Creation Date:
2025-12-24 @ 3:33 PM
Ignite Modification Date:
2025-12-30 @ 8:23 PM
Study NCT ID:
NCT01390792
Status:
COMPLETED
Last Update Posted:
2017-05-16
First Post:
2011-07-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: